Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.61 |
| ▸ | IL1RN | P18510 | 4/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 3/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.50 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211772 | 0.91 | ERAP2 (0.62) | ERAP2IL1RNERAP1ERBB2EDNRA | |
| SCHEMBL30026081 | 0.88 | ERAP2 (0.59) | ERAP2IL1RNERAP1ERBB2EDNRA | |
| SCHEMBL30512698 | 0.85 | ERBB2 (0.65) | ERAP2ERBB2EDNRAKISS1RMAGI3 | |
| SCHEMBL29794215 | 0.84 | EDNRA (0.60) | ERAP2IL1RNERAP1EDNRAMMP1 | |
| SCHEMBL30116697 | 0.84 | ERBB2 (0.64) | ERAP2ERBB2KISS1RMAGI3 | |
| SCHEMBL31388720 | 0.83 | ERAP2 (0.64) | ERAP2IL1RNERAP1EDNRAECE1 | |
| SCHEMBL30051096 | 0.83 | ECE1 (0.71) | ERAP2IL1RNERAP1ECE1 | |
| SCHEMBL31442375 | 0.82 | KISS1R (0.60) | ERAP2IL1RNERAP1MMP1CTSB | |
| SCHEMBL19492277 | 0.82 | IL23R (0.66) | — | |
| SCHEMBL9822645 | 0.81 | ECE1 (0.68) | ERAP2IL1RNERAP1MMP1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | ERAP2 2429/4885IL1RN 4402/4885ERAP1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.